
|Articles|February 15, 2004
B&L finishes purchase of new fluoroquinolone
Rochester, NY-Bausch & Lomb has completed the purchase of InSite Vision's ISV-403 compound for the treatment of ocular infections. Bausch & Lomb gave InSite Vision an undisclosed cash sum and reimbursement of certain product development expenses. In exchange, InSite Vision will give Bausch & Lomb a percentage of future product sales in all licensed countries.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
2
Manju Subramanian, MD: anti-VEGF linked to kidney function decline
3
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
4
Retina Society 2026: Could statins reduce PVR risk after RD repair?
5













